Merck KGaA (OTCMKTS:MKKGY) Short Interest Update

Merck KGaA (OTCMKTS:MKKGY - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 241,637 shares, an increase of 234.9% from the November 30th total of 72,150 shares. Based on an average daily volume of 280,839 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.0% of the shares of the stock are sold short. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 280,839 shares, the days-to-cover ratio is presently 0.9 days.Merck KGaA Trading Up 0.2%Shares of MKKGY opened at $28.45 on Friday. The business's 50-day moving average price is $26.95 and its 200-day moving average price is $26.33. The company has a quick ratio of 0.97, a current ratio of 1.49 and a debt-to-equity ratio of 0.36. Merck KGaA has a twelve month low of $24.32 and a twelve month high of $31.80. The stock has a market cap of $18.38 billion, a PE ratio of 11.33, a P/E/G ratio of 5.71 and a beta of 0.97. Merck KGaA (OTCMKTS:MKKGY - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.54 by $0.27. Merck KGaA had a net margin of 13.92% and a return on equity of 10.07%. The company had revenue of $6.17 billion during the quarter, compared to analysts' expectations of $6.08 billion. On average, equities analysts forecast that Merck KGaA will post 1.87 EPS for the current fiscal year. Merck KGaA Company Profile (Get Free Report)Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY. Merck's Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.Recommended StoriesFive stocks we like better than Merck KGaAWashington prepares for warPut $1,000 into this stock by Jan 1 [Not NVDA]Turn your "dead money" into $306+ monthly (starting this month)A month before the crashStrange Crystal Metal Outperforms Silicon Up to 100XThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Merck KGaA Right Now?Before you consider Merck KGaA, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.While Merck KGaA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here